Amgen Lung Cancer Study Shows Significant Survival Benefit in Phase 3 Trial

Key Facts

In a move that underscores the evolving landscape of immunotherapy, Amgen announced landmark Phase 3 results from its DeLLphi-305 study. The data revealed that IMDELLTRA, in combination with AstraZeneca’s Imfinzi, demonstrated a statistically significant improvement in overall survival for patients with extensive-stage small cell lung cancer (ES-SCLC). This marks the first time a Bispecific T-cell Engager (BiTE) therapy has shown a definitive survival benefit in this specific clinical setting, potentially establishing a new standard of care.

These clinical milestones are critical for mega-cap biotech firms as they seek to solidify long-term value through oncology breakthroughs. Per market data, AstraZeneca (AZN) shares stood at $162.7 at the close of September 4, 2026. The successful trial results for IMDELLTRA are expected to drive sentiment for Amgen, as the therapy targets a major indication with high unmet medical needs, according to analyst reports.

Investors are now looking toward regulatory milestones as the next primary catalysts for the sector. Based on authoritative data, AZN closed at $162.7 (close September 4, 2026), maintaining a range between $161.13 and $163.78. With no immediate pharmaceutical-specific events in the upcoming economic calendar, market attention remains focused on the long-term commercial potential of this newly validated combination therapy.